Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc covers the month of September 2026, with specific data as of August 31, 2026. Haleon is a consumer health company focused on everyday health, operating across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company markets trusted brands including Advil, Centrum, Panadol, Sensodyne, and Voltaren.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a capital disclosure rather than a financial results statement.
Material Changes and Capital Structure
- Total Shares Issued: 8,808,341,409 ordinary shares of £0.01 each.
- Treasury Shares: 11,792,625 shares held as treasury stock.
- Voting Rights: 8,796,548,784 ordinary shares with voting rights.
- Reporting Date: August 31, 2026.
The number of voting shares serves as the denominator for shareholders calculating notification obligations under the FCA's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to capital structure updates and corporate contact information.
Key Facts for Investor Verification
- Verify the total number of voting shares (8,796,548,784) for compliance with disclosure thresholds.
- Confirm the count of treasury shares (11,792,625) held by the company.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.
- Contact the Company Secretary at company.secretary@haleon.com for notifiable interest submissions.